SynthesisFrontiers in endocrinology2025
Clinical effect of intravitreal ranibizumab and laser photocoagulation on diabetic macular edema: a meta-analysis.
Synthesis in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To systematically evaluate the clinical effect of intravitreal ranibizumab (IVR) and laser photocoagulation on diabetic macular edema (DME). Method: A systematic search was conducted of five English databases from the establishment of each database to 31 January 2024, and a meta-analysis was performed using Review Manager 5.3 software. Result: A total of 1,040 patients were included across 10 articles, where 531 patients had been treated with IVR and 509 with laser photocoagulation. The results of the meta-analysis showed that visual acuity improvement in the IVR group was better than in the laser photocoagulation group. The difference was statistically significant (best corrected visual acuity [BCVA], Mean Difference (MD) = 5.69, 95% confidence interval [CI]: 4.51, 6.86, Conclusion: Intravitreal ranibizumab remains superior to laser photocoagulation in improving vision and reducing macular edema in DME, albeit with higher adverse events. These findings support IVR's continued relevance in contemporary practice, particularly where newer anti-vascular endothelial growth factor agents are unavailable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.